These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25985046)

  • 1. Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder.
    Vittengl JR; Clark LA; Thase ME; Jarrett RB
    Psychotherapy (Chic); 2015 Jun; 52(2):268-77. PubMed ID: 25985046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder.
    Vittengl JR; Clark LA; Thase ME; Jarrett RB
    J Consult Clin Psychol; 2014 Dec; 82(6):1049-59. PubMed ID: 25045908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care.
    Jarrett RB; Minhajuddin A; Vittengl JR; Clark LA; Thase ME
    J Consult Clin Psychol; 2016 Apr; 84(4):365-76. PubMed ID: 26654211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder.
    Vittengl JR; Anna Clark L; Thase ME; Jarrett RB
    Psychiatry Res; 2017 Jul; 253():174-181. PubMed ID: 28388454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.
    Jarrett RB; Thase ME
    Contemp Clin Trials; 2010 Jul; 31(4):355-77. PubMed ID: 20451668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal social-interpersonal functioning among higher-risk responders to acute-phase cognitive therapy for recurrent major depressive disorder.
    Vittengl JR; Clark LA; Thase ME; Jarrett RB
    J Affect Disord; 2016 Jul; 199():148-56. PubMed ID: 27104803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo.
    Jarrett RB; Minhajuddin A; Gershenfeld H; Friedman ES; Thase ME
    JAMA Psychiatry; 2013 Nov; 70(11):1152-60. PubMed ID: 24005123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression?
    Vittengl JR; Clark LA; Smits JAJ; Thase ME; Jarrett RB
    J Affect Disord; 2019 Jan; 242():150-158. PubMed ID: 30176494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defined symptom-change trajectories during acute-phase cognitive therapy for depression predict better longitudinal outcomes.
    Vittengl JR; Clark LA; Thase ME; Jarrett RB
    Behav Res Ther; 2016 Dec; 87():48-57. PubMed ID: 27591917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.
    Perlis RH; Nierenberg AA; Alpert JE; Pava J; Matthews JD; Buchin J; Sickinger AH; Fava M
    J Clin Psychopharmacol; 2002 Oct; 22(5):474-80. PubMed ID: 12352270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved cognitive content endures for 2 years among unstable responders to acute-phase cognitive therapy for recurrent major depressive disorder.
    Vittengl JR; Clark LA; Thase ME; Jarrett RB
    Psychol Med; 2015 Nov; 45(15):3191-204. PubMed ID: 26098793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
    Iovieno N; van Nieuwenhuizen A; Clain A; Baer L; Nierenberg AA
    Depress Anxiety; 2011 Feb; 28(2):137-44. PubMed ID: 21284066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moderators of continuation phase cognitive therapy's effects on relapse, recurrence, remission, and recovery from depression.
    Vittengl JR; Clark LA; Jarrett RB
    Behav Res Ther; 2010 Jun; 48(6):449-58. PubMed ID: 20163785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.
    Kocsis JH; Rush AJ; Markowitz JC; Borian FE; Dunner DL; Koran LM; Klein DN; Trivedi MH; Arnow B; Keitner G; Kornstein SG; Keller MB
    Psychopharmacol Bull; 2003; 37(4):73-87. PubMed ID: 15131518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life after response to acute-phase cognitive therapy for recurrent depression.
    Vittengl JR; Jha MK; Minhajuddin A; Thase ME; Jarrett RB
    J Affect Disord; 2021 Jan; 278():218-225. PubMed ID: 32971314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder.
    Kennard BD; Emslie GJ; Mayes TL; Nightingale-Teresi J; Nakonezny PA; Hughes JL; Jones JM; Tao R; Stewart SM; Jarrett RB
    J Am Acad Child Adolesc Psychiatry; 2008 Dec; 47(12):1395-404. PubMed ID: 18978634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is sleep disturbance linked to short- and long-term outcomes following treatments for recurrent depression?
    Boland EM; Vittengl JR; Clark LA; Thase ME; Jarrett RB
    J Affect Disord; 2020 Feb; 262():323-332. PubMed ID: 31735410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Could Treatment Matching Patients' Beliefs About Depression Improve Outcomes?
    Vittengl JR; Clark LA; Thase ME; Jarrett RB
    Behav Ther; 2019 Jul; 50(4):765-777. PubMed ID: 31208686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine.
    Papakostas GI; Petersen T; Denninger JW; Tossani E; Pava JA; Alpert JE; Nierenberg AA; Fava M
    J Clin Psychopharmacol; 2004 Oct; 24(5):507-11. PubMed ID: 15349006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive reactivity, dysfunctional attitudes, and depressive relapse and recurrence in cognitive therapy responders.
    Jarrett RB; Minhajuddin A; Borman PD; Dunlap L; Segal ZV; Kidner CL; Friedman ES; Thase ME
    Behav Res Ther; 2012 May; 50(5):280-6. PubMed ID: 22445946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.